Antifibrotic treatments for IPF, such as pirfenidone and nintedanib, are associated with significant side effects impacting quality of life. Despite side effects, patients perceive antifibrotics as ...

The FDA has approved Cipla's nintedanib capsules as a new generic version of Ofev for treating idiopathic pulmonary fibrosis ...

Rare telomere and non-telomere genetic variants significantly affect survival in IPF patients, with non-additive effects on common risk variants. Polygenic risk scores (PRS-IPF) may play a crucial ...

This CT scan shows the "honeycomb" pattern of scarring in the lungs of a patient with idiopathic pulmonary fibrosis, a progressive disease with few good treatment options. A new study has found that a ...

Please provide your email address to receive an email when new articles are posted on . Thirty-eight percent of patients with IPF and OSA died, whereas this rate was 46% in patients with IPF only.

Researchers at the Icahn School of Medicine at Mount Sinai and collaborators have identified a previously overlooked protein, Epac1, as a key driver of idiopathic pulmonary fibrosis (IPF), a chronic ...

Trial is evaluating the safety, tolerability, and efficacy of LTI-03 in idiopathic pulmonary fibrosis (IPF) with topline interim data expected in the first half of 2026 AUSTIN, Texas, May 27, 2025 ...